KLH conjugated synthetic peptide derived from human VWF/Von Willebrand Factor: 1651-1800/2813
Conjugate
Unconjugated
Applications
Application Notes
IHC-P: 1:100-500 IHC-F: 1:100-500 IF: 1:100-500
General Notes
This product (Catalog No. CPBT-58533RC) is a rabbit-derived IgG polyclonal antibody raised against human VWF, targeting the amino acid region 1651–1800 of the protein. This antibody exhibits cross-reactivity with VWF from mouse and rat. It has been affinity purified by protein A. This gene encodes a glycoprotein involved in hemostasis. The encoded preproprotein is proteolytically processed following assembly into large multimeric complexes. These complexes function in the adhesion of platelets to sites of vascular injury and the transport of various proteins in the blood. Mutations in this gene result in von Willebrand disease, an inherited bleeding disorder. An unprocessed pseudogene has been found on chromosome 22. CPBT-58533RC is suitable for use in IHC-P (1:100–1:500), IHC-F (1:100–1:500), IF (immunofluorescence) (1:100–1:500) applications. CPBT-58533RC is supplied as a liquid formulation in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
Target
Alternative Names
Von Willebrand Factor; Coagulation factor VIII; F8VWF; Factor VIII related antigen; von Willebrand antigen 2; Von Willebrand antigen II; Von Willebrand disease; VWD; Coagulation factor VIII; Coagulation factor VIII VWF; F8VWF; VWF_HUMAN
My Review for Rabbit Anti-Human VWF (a.a. 1651-1800) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.